Page 106 - ITPS-7-1
P. 106

INNOSC Theranostics and
            Pharmacological Sciences                                               Plants immunoactivity: In silico study



               https://doi.org/10.1016/j.cell.2009.03.046      56.  White PT, Subramanian C, Motiwala HF, et al., 2016, Natural
                                                                  withanolides in the treatment of chronic diseases. Adv Exp
            52.  Yu CF, Liu ZX, Cantley LG, 2002, ERK negatively regulates   Med Biol, 928: 329–373.
               the epidermal growth factor-mediated interaction of
               Gab1 and the phosphatidylinositol 3-kinase.  J  Biol Chem,      https://doi.org/10.1007/978-3-319-41334-1_14
               277: 19382–19388.                               57.  Swarnalatha S, Puratchikody A, 2014, Cytokine mediated
               https://doi.org/10.1074/jbc.M200732200             immunomodulatory properties of kaempferol-5-O-β-D-
                                                                  glucopyranoside  from  methanol  extract  of  aerial  parts  of
            53.  Narayanankutty A, 2019, PI3K/Akt/mTOR pathway    Indigofera aspalathoides Vahl ex DC. Int J Res Pharm Sci,
               as a therapeutic target for colorectal cancer: A  review   5: 73–78.
               of preclinical and clinical evidence.  Curr Drug Targets,
               20: 1217–1226.                                  58.  Choi MJ, Park EJ, Min KJ, et al., 2011, Endoplasmic reticulum
                                                                  stress mediates withaferin A-induced apoptosis in human
               https://doi.org/10.2174/1389450120666190618123846  renal carcinoma cells. Toxicology In Vitro, 25: 692–698.
            54.  Chang WJ, Gonzalez-Paz N, Price-Troska T, 2008, Clinical      https://doi.org/10.1016/j.tiv.2011.01.010
               and biological significance of RAS mutations in multiple
               myeloma. Leukemia, 22: 2280–2284.               59.  Abramson HN, 2016, Kinase inhibitors as potential agents in the
                                                                  treatment of multiple myeloma. Oncotarget,7: 81926–81968.
               https://doi.org/10.1038/leu.2008.142
                                                                  https://doi.org/10.18632/oncotarget.10745
            55.  Rasmussen T, Kuehl M, Lodahl M, et al., 2005, Possible roles
               for activating RAS mutations in the MGUS to MM transition   60.  Manning G, Whyte DB, Martinez R,  et al., 2002, The
               and in the intramedullary to extramedullary transition in   protein kinase complement of the human genome. Science,
               some plasma cell tumors. Blood, 105: 317–323. https://doi.   298: 1912–1934.
               org/10.1182/blood-2004-03-0833                     https://doi.org/10.1126/science.1075762

















































            Volume 7 Issue 1 (2024)                         17                        https://doi.org/10.36922/itps.1076
   101   102   103   104   105   106   107   108   109   110   111